University of Louisville spinout Talaris has filed for an initial public offering on the Nasdaq Global Market.

Talaris Therapeutics, a US-based cell therapy developer spun out of University of Louisville, has filed for a $100m initial public offering on the Nasdaq Global Market. The company, which previously operated as Regenerex, has yet to set any terms for the proposed offering. Founded in 2002, Talaris is developing cell therapies that help prevent the…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.